Pancreatic Cancer Research

ResearcherJiaxing UniversityActive in the last 2 years

Lingyu Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5698-7700; OpenAlex author ID A5101623967. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2021: 4 papers · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 8

  1. DCAF13 is associated with pancreatic ductal adenocarcinoma progression and p53-related signaling in TP53-mutant cells. Co-author DOI 10.1016/j.bbrc.2026.154207↗
  2. Research progress of plant-derived chemical compounds for overcoming pancreatic cancer drug resistance. Co-author DOI 10.3748/wjg.v32.i9.115131↗
  3. TNFRSF9 Inhibits Pancreatic Cancer Progression by Regulating PAX6-mediated Cell Proliferation, Migration, and Apoptosis. Last author DOI 10.1097/mpa.0000000000002497↗
  4. Reversing VTN deficiency inhibits the progression of pancreatic cancer and enhances sensitivity to anti-PD1 immunotherapy. Co-author DOI 10.3389/fimmu.2025.1578870↗
  5. The expression and clinical prognostic value of protein phosphatase 1 catalytic subunit beta in pancreatic cancer. Co-author DOI 10.1080/21655979.2021.1934243↗
  6. The prognostic value of intratumoral and peritumoral tumor-infiltrating FoxP3+Treg cells in of pancreatic adenocarcinoma: a meta-analysis. Co-author DOI 10.1186/s12957-021-02420-1↗
  7. CXCL10 Expression in Tumor Tissues and is An Independent Prognostic Indicator of Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-966327/v1↗
  8. Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy. First author DOI 10.3892/etm.2021.10574↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhengxiang Zhong · 4 shared papers, 2021 · strength 0.64
  2. Xiaoguang Wang · 3 shared papers, 2021–2026 · strength 0.54
  3. Haokai Xu · 3 shared papers, 2021 · strength 0.46
  4. Zhengwei Song · 2 shared papers, 2021–2025 · strength 0.39
  5. Bin Yan Wu · 2 shared papers, 2021 · strength 0.31
  6. Xiaorong Liu · 1 shared paper, 2025 · strength 0.30
  7. Xiaofang Fan · 1 shared paper, 2026 · strength 0.28
  8. Bin Wu · 1 shared paper, 2026 · strength 0.28
  9. Jiaqi Yu · 1 shared paper, 2026 · strength 0.28
  10. Jia-Qi Yu · 1 shared paper, 2026 · strength 0.26
  11. Xiaoguang Wang · 1 shared paper, 2025 · strength 0.26
  12. Siqi Zhao · 1 shared paper, 2025 · strength 0.26
  13. Bin Wu · 1 shared paper, 2021 · strength 0.19
  14. Yiyu Shen · 1 shared paper, 2021 · strength 0.17
  15. Fei Chen · 1 shared paper, 2021 · strength 0.14
  16. Wei Chen · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.